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doi:10.1016/j.jtcvs.2004.04.027414 The Journal of Thoracic and CardioBackground: Postoperative chemotherapy is currently not recommended for re-
sected non–small cell lung cancer in many countries and centers. Recently, results
of several large randomized clinical trials were reported with conflicting evidence.
Accordingly, we sought to determine whether postoperative chemotherapy is asso-
ciated with improved survival compared with that after surgical intervention alone.
Methods: Randomized clinical trials with cisplatin- or uracil plus ftorafur–contain-
ing regimens were included and evaluated separately. A systematic review that
included randomized clinical trials performed before 1995 was identified and found
to be of adequate quality. Further randomized controlled trials were identified by
searching MEDLINE, EMBASE, and the Cochrane Controlled Trials Register from
1995 through 2004. In addition, the reference lists of articles and conference
abstracts were searched. The logarithm of the hazard ratio and its standard error
were calculated, and a fixed-effect model was used to combine the estimates.
Results: There were 7200 patients enrolled in 19 trials included in the analyses. An
overall estimate of 13% relative reduction in mortality (95% confidence interval,
7%-19%) was found. There was 11% relative reduction in mortality associated with
postoperative cisplatin (95% confidence interval, 4%-18%; P  .004) and 17%
associated with uracil plus ftorafur (95% confidence interval, 5%-27%; P  .006)
compared with that after surgical intervention alone. This means that there would be
an additional survivor at 5 years for 25 patients treated with cisplatin or for 30
patients treated with uracil plus ftorafur.
Conclusions: Postoperative chemotherapy is associated with improved survival
compared with that after surgical intervention alone. Selected patients with com-
pletely resected non–small cell lung cancer should be offered chemotherapy.
More than 75,000 procedures in the United States and 3000procedures in the United Kingdom are performed for earlystage lung cancer,1,2 but even for patients with stage I and IInon–small cell lung cancer (NSCLC), there is a death rate of20% to 40% at 5 years with surgical intervention alone.3 TheNon–small Cell Lung Cancer Collaborative Group
(NSCLCCG) published a systematic review and meta-analysis in 1995, and a
substantial section of the review was related to the issue of adjuvant chemotherapy
use after surgical intervention.4,5 This section of this review, based on 12 random-
ized trials comparing adjuvant chemotherapy with surgical intervention alone,
reported a tendency toward a reduction in mortality of 13% associated with
cisplatin-based chemotherapy (P  .08) and of 11% associated with uracil plus
ftorafur (tefagur; UFT)–based chemotherapy (P  .31). Because these results were
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TSnot statistically significant, conventional wisdom is that
postoperative chemotherapy should not be recommended
after complete resection of early stage lung cancer, given
the toxicity associated with the chemotherapy.6
Recently, the results of several large randomized clinical
trials (RCTs) were reported, with conflicting evidence. Al-
though the International Adjuvant Lung Cancer Trial
(IALT)7 reported survival benefit associated with cisplatin
chemotherapy, 2 other large trials, Adjuvant Lung Project
Italy (ALPI)8 and the Big Lung Trial,9 did not report any
survival advantage. If the effect of postoperative chemo-
therapy were true, given the large number of procedures
conducted in the United Kingdom and the United States, a
difference in survival that is perceived to be small (esti-
mated at 4%-5%) would mean that more than 3000 deaths in
the United States and more than 150 deaths in the United
Kingdom would be expected to be averted annually. Ac-
cordingly, we systematically searched for new evidence
since the publication of the NSCLCCG review in 1995 and
aimed to perform a meta-analysis of relevant trials to de-
termine whether postoperative chemotherapy is associated
with improved survival compared with that after surgical
intervention alone. Because a small survival benefit repre-
sents a value judgment, we also sought to interpret the
differences in survival from a clinical relevance perspective.
Methods
Types of Studies and Participants
The trials of mostly node-negative patients were included in this
review. The trials of mostly node-positive patients include com-
parison of postoperative chemotherapy plus radiotherapy versus
radiotherapy alone, are applicable to different group of patients,
and should be analyzed separately.3 Additionally, node-positive
patients compose the minority of patients undergoing surgical
intervention for lung cancer, and there is some evidence that
postoperative radiotherapy is detrimental for patients with stage I
and II NSCLC.10 Thus node-positive trials require separate sys-
tematic review and are not included in this overview.
Only RCTs with cisplatin- or UFT-containing regimens were
included in this overview. The trials of alkylating agents were not
included because they were found to be harmful in the NSCLCCG
review4 and are no longer used in current practice.
The trials of cisplatin- and UFT-containing regimens were
evaluated in separate subgroup analyses. The following inclusion
criteria were applied: (1) random allocation of study treatments,
(2) use not combined with another experimental medication or
procedure, and (3) postoperative use of chemotherapy.
For each trial, data on survival were collected in the interven-
tion and control groups by one author (AS) and verified by all
authors.
Search Strategy for Identification of Studies
The systematic review by NSCLCCG was found to be of adequate
quality until 1995. All trials included in this review were included
in the meta-analyses. New RCTs were identified by searching
MEDLINE, EMBASE, and the Cochrane Controlled Trials Reg-
The Journal of Thoraciister from 1995 through 2004. A standard filter identifying RCTs
was used for searching MEDLINE and EMBASE. These search
algorithms are available at the Scottish Intercollegiate Guideline
Network Web site (http://www.sign.ac.uk/methodology/filters.
html). In addition, we searched the reference lists of RCTs, re-
views, and conference reports to look for additional studies. Ab-
stracts were included to minimize publication bias.11 Search of the
databases, reference lists of articles, and conference reports iden-
tified 42 relevant abstracts related to postoperative chemotherapy.
Seven unique trials met our inclusion criteria.7-9,12-15
Statistical Analyses
The logarithm of the hazard ratio (HR) and its SE were calculated
from the original reports.16 Then a meta-analysis of the trials was
performed stratified by each subgroup of medication (cisplatin and
UFT). The test of homogeneity did not provide evidence for
heterogeneity among the studies (2 of 9.60, df of 11, and P of .57
for cisplatin and 2 of 10.86, df of 6, and P of .09 for UFT).
Therefore a fixed-effect model was used to combine the estimates.
Additionally, cumulative meta-analyses were performed in which
each trial’s effect was added to the estimate observed in all
previous studies. Finally, subgroup analyses of Japanese and Eu-
ropean/North American participants in cisplatin trials were per-
formed.
Funnel plot analyses were performed to determine publication
bias in the trials. RevMan 4.2 was used in all analyses.
Results
The previous 12 trials of adjuvant chemotherapy included in
the NSCLCCG review randomized a total of 1172 patients
into the chemotherapy arm and 1140 patients into the con-
trol arm.4 In 7 new trials there were 2456 patients random-
ized to adjuvant chemotherapy and 2432 to surgical inter-
vention alone. Altogether, there were 7200 patients enrolled
in 19 trials that were included in the meta-analyses.
An overall estimate of 13% relative reduction in mortal-
ity (HR, 0.87; 95% confidence interval [CI], 0.81-0.93; P 
.0001) associated with adjuvant chemotherapy was found.
Meta-analyses by subgroups of cisplatin chemotherapy and
UFT were performed separately. Analysis of funnel plots
did not reveal the presence of substantial publication bias.
Cisplatin-based Regimens
Four new studies randomized a total of 1770 patients into a
postoperative cisplatin-based regimen and 1748 patients
into a control arm. Two studies7,14 reported a survival
benefit, and 2 others8,9 reported no survival advantage as-
sociated with postoperative chemotherapy (Figure 1). We
have calculated the HR and 95% CIs before and after
combining the new studies with those included in the
NSCLCCG report of 1995. The results before and after
inclusion of the new studies are 0.87 (95% CI, 0.74-1.02;
P  .08) and 0.89 (95% CI, 0.82-0.96; P  .003), with
narrowed CIs and statistical significance (Figures 1 and 2).
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American trials has shown no evidence for a survival
difference between participants in these countries (Figure
3).
UFT-based Regimens
Three new studies randomized 686 patients into the UFT
arm and 684 patients into a control arm (surgical interven-
tion alone). Two reports from one study12,17 and another
separate investigation15 reported a statistically significant
survival advantage, whereas the third study showed a trend
toward improved survival associated with UFT (Figure 1).13
After combining the estimates from these studies with those
included in the NSCLCCG report, the HR has changed from
0.89 (95% CI, 0.72-1.10) to 0.83 (95% CI, 0.73-0.95; P 
.006; Figures 1 and 2). Sensitivity analyses involving ex-
clusion of two 15-year-old studies (Figure 1, UFT section,
Sawamura_88 and Sawamura_88) have shown an even
larger reduction in mortality with UFT-based therapy (HR,
Figure 1. Meta-analysis of postoperative chemothera
subcategory and the first 4 studies in the UFT subcateg
axis is based on a log scale for HR (corresponds to rela
correspond to HR estimates and 95% CIs for individual
or 2.0.0.78; 95% CI, 0.68-0.90; P  .0007).
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In this study we found that postoperative chemotherapy
with both cisplatin- and UFT-based regimens is associated
with survival benefits compared with that after surgical
intervention alone for NSCLC. We found an 11% relative
reduction in mortality associated with cisplatin and a 17%
relative reduction associated with UFT. The cisplatin-based
trials enrolled patients with stage I to IIIA disease (mostly
I-II).3,7-9 Survival in the control group (surgical intervention
alone) was approximately 45% at 5 years. As a result, the
11% relative reduction in mortality translates into an ap-
proximately 4% absolute improvement in survival. Thus, it
would be necessary to treat approximately 25 patients to
prevent one additional death at 5 years. In contrast, UFT-
based regimens were mostly used for stage I disease, with
few patients having stage II disease.12,13,15 Survival in the
control group (surgical intervention alone) was approxi-
mately 80% at 5 years. Accordingly, a 17% relative reduc-
tion in mortality transforms into an approximately 3.5%
rials for NSCLC. The first 8 studies in the cisplatin
ere originally combined by NSCLCCG. The horizontal
risk) ranging from 0.5 to 2.0. The black boxes and lines
ies. Arrows show that the 95% CI extends beyond 0.5py t
ory w
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TStake about 30 treated patients to prevent one additional
death at 5 years.
All UFT trials have been conducted in Japan, whereas
cisplatin trials were performed in a number of countries,
including Japan, Europe, and North America. In subgroup
analyses we found no evidence for a survival difference
between Japanese and European/North American partici-
pants in cisplatin trials (Figure 3), and therefore there is no
a priori reason to reject the applicability of UFT findings to
Figure 2. Cumulative meta-analysis of postoperative ch
to the date of the first report. The first 8 studies in th
subcategory were originally combined by NSCLCCG
(corresponds to relative risk) ranging from 0.5 to 2.0. T
95% CIs for individual studies. Arrows show that the
individual trial is added to the estimate observed in a
the direction of the association is the same, then no d
shrink because of increased sample size.
Figure 3. Subgroup analyses of cisplatin-based posto
North American participants.Europe and North America. Because UFT is not yet avail-
The Journal of Thoraciable in North America and Europe, it might be important to
invigorate previous efforts to initiate RCTs and to investi-
gate the applicability of these encouraging findings.
One limitation of our study was that we did not perform
formal quality evaluation for the studies included in the
overview; however, most included studies were large mul-
ticenter trials, and their quality is hardly questionable. One
other limitation might be publication bias (negative studies
not being reported). However, funnel plots were not indic-
herapy trials for NSCLC. Studies are ordered according
platin subcategory and the first 4 studies in the UFT
e horizontal axis is based on a log scale for HR
lack boxes and lines correspond to HR estimates and
CI extends beyond 0.5 or 2.0. The estimate of each
vious studies to perform cumulative meta-analyses. If
ence in the overall estimate is observed, but 95% CIs
tive chemotherapy trials by Japanese and European/emot
e cis
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95%
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ifferperaative of substantial publication bias, and our sensitivity
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more than 1000 patients that would show a statistically
significant 20% higher risk of mortality for cisplatin che-
motherapy (which is very unlikely), the overall estimate
would still favor cisplatin chemotherapy and would be
statistically significant.
The results of the postoperative chemotherapy studies
are supported by those of published studies of preoperative
and perioperative chemotherapy that likewise demonstrate a
benefit in survival.18-20 The largest of these20 randomized
355 eligible patients to induction and postoperative chemo-
therapy versus surgical intervention alone. Although sur-
vival differences did not achieve overall significance in this
study, there was an 8.6% absolute reduction in mortality in
the chemotherapy treatment arm after 4 years.
Previous guidelines were heavily influenced by the find-
ing that the effect of postoperative chemotherapy was not
statistically significant (P  .08 for cisplatin and P  .31
for UFT), and survival benefit at 5 years for cisplatin was
considered small in the light of possible toxicity.6 After the
IALT study results were reported, most centers in North
America started to recommend at least chemotherapy con-
sultation for all patients with stage IB to IIIA disease.
However, this evidence did not receive as much attention in
the United Kingdom and many European countries. There
was concern that IALT is only one individual study that has
shown this benefit. Our meta-analysis determined that the
evidence of survival advantage was available before the
IALT results were published and does not change even after
adding the results of other recent large trials. Meta-analysis
has an advantage of pulling many underpowered clinical
trials to determine that survival advantage of 4% is not by
chance alone.
It is also important to assert that a small increase in
survival is common to many oncologic strategies, and a
benefit of this size is considered acceptable for the prescrip-
tion of adjuvant chemotherapy in colorectal and breast
cancers. Moreover, there is some evidence to suggest that
the magnitude of the benefit associated with postoperative
chemotherapy might be improved in the future. For exam-
ple, the cisplatin and etoposide or vindesine or vinblastine
regimens used in a majority of patients in these studies are
inferior to regimens such as mitomycin, ifosfamide, and
cisplatin or mitomycin, vinblastine, and cisplatin and the
cisplatin doublet regimens incorporating newer cytotoxic
agents, which are currently used as a standard therapy in
metastatic disease.21-23
The effectiveness of UFT-based regimens has not been
discussed previously because the estimate of the absolute
survival difference was even smaller than the estimate for
cisplatin-based chemotherapy, and the difference was much
more likely to occur by chance alone (P  .31). Because
UFT-based regimens are generally less toxic than cisplatin-
418 The Journal of Thoracic and Cardiovascular Surgery ● Septbased regimens, with severe toxicity occurring in less than
3% of patients,3,12,13 further research should elucidate
whether UFT-based regimens might be considered as alter-
natives to cisplatin and as treatments of choice for postop-
erative chemotherapy, particularly for stage I disease. The
mode of action of long-term UFT therapy might be different
from that of a standard cytotoxic agent.24 This raises the
possibility that cisplatin-based chemotherapy followed by
maintenance UFT might optimize outcomes for patients
with resected NSCLC.
Mostly stage I to II, otherwise healthy patients with good
performance status (Karnofsky, 80; Eastern Cooperative
Oncology Group, 2) were enrolled in the trials of postop-
erative chemotherapy. In addition, some patients received
adjuvant radiotherapy in these trials, and its effect on sur-
vival requires further evaluation because there is some
evidence that postoperative radiotherapy is detrimental for
stage I and II NSCLC but might reduce local relapse for
stage IIIA disease.10
Conclusions
Selected patients with completely resected NSCLC should
be offered postoperative chemotherapy. This would influ-
ence the current practice of postoperative management after
a major lung resection procedure. Further research should
elucidate patient preferences regarding the tradeoff between
improved life expectancy and toxicity and establish the role
of UFT and other oral fluoropyrimidines in the management
of resected NSCLC.
We thank Veena Paes, Louise Thomas, and Rachel Southon for
their work on the initial searches, identifying the hard copies of the
studies, and other logistical support.
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